Serious Events with Infliximab in Patients with Inflammatory Bowel Disease: A 9-Year Cohort Study in the Netherlands

Author： de Vries Hilbert S. van Oijen Martijn G.H. de Jong Dirk J.

ISSN： 0114-5916

Source： Drug Safety, Vol.31, Iss.12, 2008-01, pp. : 1135-1144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease

By Veres Gabor

Drugs, Vol. 67, Iss. 12, 2007-01 ,pp. : 1703-1723

Adis International

Access to resources Recommend Favorite

Anti Tumor Necrosis Factor-a Monoclonal Antibody (Infliximab) Therapy in Patients with Inflammatory Bowel Disease (IBD): Applications and Side Effects

Drug Design Reviews - Online, Vol. 1, Iss. 2, 2004-01 ,pp. : 111-117

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics of Cyclosporin Microemulsion in Patients with Inflammatory Bowel Disease

By Latteri M.

Clinical Pharmacokinetics, Vol. 40, Iss. 6, 2001-01 ,pp. : 473-483

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of Therapy in Inflammatory Bowel Disease Patients

Current Pharmacogenomics, Vol. 5, Iss. 3, 2007-09 ,pp. : 235-247

Bentham Science Publishers

Access to resources Recommend Favorite

Inadequate sunlight exposure in patients with inflammatory bowel disease

Journal of Digestive Diseases, Vol. 19, Iss. 1, 2018-01 ,pp. : 8-14

John Wiley & Sons Inc

Access to resources Recommend Favorite